# Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Source: https://onco.cc/trials/nct06682195/  
OnCo record `nct06682195` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab in triple-negative breast cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.

## Summary

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) is a phase 2, interventional study registered as NCT06682195 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 35 participants, started 2024-10-09 and due to reach its primary completion in 2026-10-01. Interventions recorded: Neoadjuvant chemotherapy combined with Toripalimab. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "All patients had triple negative breast cancer confirmed by histopathology;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06682195
- Phase: 2
- Setting: Neoadjuvant Chemotherapy Combined With Toripalimab for Triple-negative Breast Cancer : a Prospective, Single-arm, Multi-center Study (NEOTORCH-BREAST02)
- Sponsor: First Affiliated Hospital of Zhejiang University
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT06682195: https://clinicaltrials.gov/study/NCT06682195

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06682195.json